

計畫編號：DOH98-TD-G-111-018

行政院衛生署九十八年度科技研究計畫

建置肺癌組織及其臨床資訊核心

研究報告

執行機構：中國醫藥大學附設醫院

計畫主持人：陳志毅

研究人員：吳佳芳

執行期間：97 年 5 月 1 日至 98 年 12 月 31 日

*本研究報告僅供參考，不代表本署意見，依合約之規定：如對
媒體發布研究成果應事先徵求本署同意*

目次:

- ◆ 中文摘要 P2-3
- ◆ 英文摘要: P4-5
- ◆ 本文: P6-7
- ◆ 材料方法: P8-9
- ◆ 結果: P10-12
- ◆ 結論與建議 P13
- ◆ 98 年度重要研究成果及對本署之具體建 P14
- ◆ 參考文獻: P15-16
- ◆ 附錄一 空白研究跳查問卷 P18-32
- ◆ 附錄二 Code Book P33
- ◆ 附錄三 原始數據檔 P34

摘要：

肺癌是最常見的癌症死因，約佔癌症死亡人數的 17%。雖然現今醫療技術進步快速，然而肺癌的 5 年存活率只有 12-15%。非小細胞肺癌是肺癌的主要類型。大約有 30% 的患者可以在疾病早期診斷並接受手術治療。然而，40% 的病人在五年內有復發的情形。此外，轉移是肺癌治療失敗的另一主要原因。因此肺癌的早期診斷和改善預後是相當重要的。

藉由蛋白質體學、分子生物學的發展，將有助於找到肺癌的相關危險因子，釐清致癌機轉，以改善肺癌的治療方式甚或是達到預防肺癌的目的。因此，臨床和病理資訊的整合對於臨床治療和基礎研究而言，是不可或缺的。為此我們計畫建置肺癌組織及其臨床資訊核心，作為一個研究平台，提供完善的檢體和臨床病理資料以供研究人員進行分析、統計。我們將遵守標準作業流程，使其有效且正確地操作和儲存檢體，並建立肺癌病人的臨床病理資料（包括：家族史、抽菸有無、預後）。我們預期所得到的結果將可應用在生物標記、危險因子和流行病學分析等方面，相信對於肺癌研究的進展將有一定程度的裨益。

本年度之計劃預計完成四個主要項目：1. 建立組織庫之標準作業程序 2. 臨床病理資訊建檔 3. 組織及血液檢體收集 4. 個案追蹤。截至 98 年 10 月 31 日止，標準作業程序已建立完成、臨床病理資訊建檔以及個案追蹤作業亦逐一完成，臨床檢體共收集 123 件個案數目。自民國 97 年 5 月 1 日起至民國 98 年 10 月 31 日止各月收案進度如下表。

肺癌組織及其臨床資訊核心各月收案進度表

月份	肺癌開刀數	同意訪視問卷	同意檢體使用	病理結果符合收案條件	具有問卷、檢體、病理結果符合之收案人數
五月	12	8	5	3	3
六月	6	4	3	2	2
七月	12	8	4	4	4
八月	2	2	2	2	2
九月	12	9	9	6	6
十月	19	17	17	14	14
十一月	13	10	10	6	6
十二月	14	13	13	12	12
一月	7	6	6	5	5
二月	12	11	11	9	9
三月	12	12	12	8	8
四月	10	8	8	6	6
五月	12	11	11	7	7
六月	16	15	15	7	7
七月	14	12	12	8	8
八月	12	12	12	9	9
九月	9	9	9	8	8
十月	12	11	11	7	7
總計	206	178	170	123	123

中文關鍵詞(至少三個)：肺癌、臨床資訊、組織庫核心實驗室

Abstract:

Lung cancer is the most common cause of death from cancer worldwide. Among cancer mortality patients, 17% were caused by lung cancer. Although current improvement of medical science, the overall 5-year survival time in lung cancer is 9% ~ 12%. Non-small cell lung cancer (NSCLC) is the main cell type of lung cancer. There are only 30% NSCLC can be diagnosed in their early stage. Among them, 40% will relapse within 5 years after potentially curative treatment. Thus, current staging methods are inadequate for predicting the outcome of treatment of NSCLC.

By using advance of proteomics and molecular biology, it can help us to find various relative risk factors, to clarify carcinogenesis, to improve therapeutic methods, and even to prevent NSCLC. Therefore, it is essential to collaborate the information of both clinical therapy and basic study. Our goal is to set up a lung cancer tissue core laboratory and clinical information core facility. As a research platform, it will offer high quality specimens and complete clinical data to researchers for further statistical analysis. We will obey standard operation process to manipulate and store the specimens efficiently and accurately. Additionally, we will build up clinical data of NSCLC database, including family history, smoking status, and prognosis. We anticipate that it will become a very good supporting research source in biomarkers, risk factors, and epidemiology analysis of all other projects for improvement of lung cancer research.

There are 4 main objects to complete this year. (1) to establish SOP of tissue bank (2) to establish clinical pathology data (3) to collect tissue and blood (4) follow up for each case. We've complete all the objects now, and collect 123 specimen from May 1st,2008 to Oct.31,2009. The scheduled progress per month are list below (data from 2008/5/1 to 2009/10/31)

Month	Lung cancer op patient No.	(Q) Agree to fill out Questionary No.	(S) Agree to tissue sample reserved for future application No.	(P) Tissue sample pathology positive No.	Q · S · P triple positive case No.
May	12	8	5	3	3
June	6	4	3	2	2
July	12	8	4	4	4
Aug	2	2	2	2	2
Sep	12	9	9	6	6
Oct	19	17	17	14	14
Nov	13	10	10	6	6
Dec	14	13	13	12	12
Jan	7	6	6	5	5
Feb	12	11	11	9	9
Mar	12	12	12	8	8
Apr	10	8	8	6	6
May	12	11	11	7	7
June	16	15	15	7	7
July	14	12	12	8	8
Aug	12	12	12	9	9
Sep	9	9	9	8	8
Oct	12	11	11	7	7
Sub.	206	178	170	123	123

(Sum from May 1,2008 to October 31,2009)

Keyword: lung cancer 、 clinical information 、 tissue core laboratory

本文：

Background and Significance.

Lung cancer is the most common cause of death from cancer worldwide, including Taiwan. Thus, lung cancer study has also become one of the major fields of National Research Program for Genomic Medicine (NRPGM). The relapse rate among patients with early-stage NSCLC (non-small cell lung cancer) is 40% within 5 years after potentially curative treatment. According to the reports from the western countries, the overall 5-year survival is only 12-15%. Current staging methods are inadequate for predicting the outcome of treatment of NSCLC.

The mechanism of lung carcinogenesis is still undetermined. There are several risk factors of lung cancer which have been reported, such as cigarette smoking, cooking fume and asbestos. Cigarette smoking is the best-known risk factor of lung cancer in the world. In fact, there are over 85% of lung cancer patients with a habit of smoking. Although cigarette smoking has gradually decreased in the United State during the past two decades, lung cancer incidence has still increased annually, especially in non-smoker females. There are several explanations which have been reported to resolve the question of whether or not women are more susceptible than men to lung cancer, including hormonal factors, and the susceptibility to DNA damage.

The target therapy and chemotherapy for lung cancer have been improved dramatically in recent years. Nevertheless, only small parts of patients with lung cancer are effective for these treatments. Therefore, the high-risk group analysis and prognosis factor identification are imperious for lung cancer prevention and treatment. A good tissue core laboratory is the foundation of basic research, such as medical biology and epidemiology.

Adequate primary tumor tissue specimen is very important for genomic study. For genetic aberrations, such as point mutation, deletion, loss of heterozygosity, or amplification, all of them need to be confirmed in the DNA sample of primary tumor tissue specimens. For functional study, although cell culture and animal model are both very useful, confirmation of the result with the RNA sample from primary tumor specimens for transcription and expression assay is also very important. The process of freezing and preservation of the frozen tumor specimens are usually quite variable

between different institutes and different researchers, which could greatly affect the results of different study groups. Thus, a standardized protocol is important for assurance of good quality. Complete clinical and pathological information is also very important. In addition, correct sampling of the tumor and adjacent non-tumor tissue is also a key issue in tissue core. Usually the operative specimens are more adequate for molecular and genomic studies.

Our goal is to set up a lung cancer tissue core laboratory and clinical information core facility. The fresh tumor tissue will be frozen and processed in a standard way along with collection of patient's blood sample and complete clinico-pathological data. This lung cancer tissue core facility will become a very good supporting research source of all other projects for lung cancer.


Specific Aims.


The aim of the project is to establish a lung cancer tissue core laboratory and clinical information database. We collected specimens from NSCLC patients who received surgery in the past. At the same time, we recorded and update clinical information, such as basic data, staging, and histological type. These specimens and information had been translated in gene expression , epidemiology, and risk factors analysis. The coordination of clinical and pathological information plays a key role in the translational study. Therefore, we develop a standard protocol to build up a good tissue core laboratory and clinical information database of lung cancer. The fresh tumor tissue will be frozen and processed in a standard way along with collection of patient's blood sample and complete clinico-pathological data.

Our plan is to collect 400 lung cancer cases in 3 years. The personnel of tissue core management follow the standard protocol to manipulate and store the specimens, and build up a database of complete clinico-pathological data. The core facility will serve the investigators in Lung Cancer Section of NRPGM, in particular will collaborate with subprojects 4, 5 and 6 of this program project, in which they need lung cancer tissue for clinical verification of the developed biomarkers. A research user committee will be organized to screen the applications and monitor the functional efficiency of the core facility.

材料與方法:

1. A working team including the surgeons, the pathologist and research assistants will be organized.
2. A standard protocol for processing the fresh tumor tissue and blood sample will be established. A check list for the tissue core laboratory will be used.
3. The collected lung tissue and clinical information will be sent to NHRI Dr. Huang's laboratory to build up a tissue core and database core facility. The following is the standard protocol:





4. The clinical information should include the following items:

ID No., age, sex, occupation, smoking history, family history, menstruation history for female, systemic disease, other malignancy, operative method, pathology diagnosis, pathological stage, treatment protocol, adjuvant therapy, complications, recurrence, and survival.

5. A Research User Committee will be organized to be in charge of setting up the rules for application of the tumor core specimens, approval of the applications and survey the functional efficiency of the core facility. The committee members will include the Principle Investigators of this program project, the Principle investigator of lung cancer tumor core project and the collaborating investigators in this project.

結果

本年度之計劃預計完成四個主要項目:1.建立組織庫之標準作業程序 2.臨床病理資訊建檔 3.組織及血液檢體收集 4.個案追蹤。截至 98 年 10 月 31 日止，標準作業程序已建立完成、臨床病理資訊建檔以及個案追蹤作業亦逐一完成，臨床檢體共收集 123 件個案數目。

1. 建立組織庫之標準作業程序

目前已建立組織檢體、血液檢體之標準化處理流程。每星期由計劃主持人篩選非小細胞肺癌之臨床個案，由助理執行危險因子問卷訪談，並且於開刀當日將個案的組織立即切割處理。血液檢體以 serum、plasma、buffy coat 分別冷凍保存於-80。組織檢體以細胞捺印技術監控其品質，將切割後的組織檢體表面平均捺印在玻片上，觀察正常組織檢體中是否含有腫瘤細胞，以及腫瘤組織中腫瘤細胞的百分比。其中保留一對組織浸泡在福馬林中 24 小時後，轉移至 75%酒精儲存，預備將來製成組織臘塊。切割後的組織立即分裝於含有 RNA later 的冷凍管中，置放 24 小時後，移轉至-80 冰箱保存，預備將來萃取 RNA。開刀後兩週，病人之病理報告確認，將病理結果符合收案條件之個案檢體以冷凍及冷藏方式寄送至國衛院保存，問卷紙本以及臨床資訊紙本以掛號方式寄至國衛院。

2. 臨床病理資訊建檔

病理報告符合收案條件之個案，將臨床病理資訊建檔，建檔紀錄的方式有 1. 紙本：問卷訪談危險因子及家族史資料、血液資料表、病歷摘要。2. 電子資料：紀錄個案之開刀日期、病灶部位、開刀方式、術後診斷、腫瘤大小、腫瘤分化程度、病理分期、個人過去病史、過去開刀紀錄、復發日期部位、轉移日期部位、正常組織捺印後是否有包含癌細胞、是否有 GGO、是否有多發的初次肺癌、是否有延遲診斷等臨床資訊。

3. 組織及血液檢體收集進度

本計畫上半年主要重點在於建立標準流程、增購儀器設備及規劃實驗室環境，至 98 年 10 月 31 日止共收個案 123 件，目前肺腫瘤開刀數有達到 206 位病人，但病理結果符合收案條件為 123 個案。因問卷訪視的流程熟悉度逐月改善，收案進度於 97 年起至年底收案共有 49 位平均一個月為 6.1 位，但至 98 年 1 至 5 月有 35 位個案數平均一個月有 7 位，而由 98 年 6 月至 10 月為 39 位個案數平均一個月有 7.8 位，由個案數來說明，個案數有逐漸增加之趨勢，未來將納入其他醫院之檢體。預計在明年陸續達到收案預期目標。

自民國 97 年 5 月 1 日起至民國 98 年 10 月 31 日止各月收案進度如下表。

月份	肺腫瘤開刀數	同意訪視問卷	同意檢體使用	病理結果符合收案條件	具有問卷、檢體、病理結果符合之收案人數
五月	12	8	5	3	3
六月	6	4	3	2	2
七月	12	8	4	4	4
八月	2	2	2	2	2
九月	12	9	9	6	6
十月	19	17	17	14	14
十一月	13	10	10	6	6
十二月	14	13	13	12	12
一月	7	6	6	5	5
二月	12	11	11	9	9
三月	12	12	12	8	8
四月	10	8	8	6	6
五月	12	11	11	7	7
六月	16	15	15	7	7
七月	14	12	12	8	8
八月	12	12	12	9	9
九月	9	9	9	8	8
十月	12	11	11	7	7
總計	206	178	170	123	123

4. 個案追蹤


第一次個案追蹤已於 97 年 9 月已完成。臨床資訊中，有紀錄個案開刀日期以及最近一次追蹤日期，開刀後第一年每三個月追蹤一次、開刀後第二年每四個月追蹤一次、開刀後第三年每六個月追蹤一次、開刀後第四年每年追蹤一次。本計劃未來將陸續以該追蹤標準方式，追蹤個案之存活、復發率。而少許病人雖然未回中國附醫回診，但仍可在其他醫院追蹤到，追蹤資料中附註已確定病人固定回診。

討論:

肺腫瘤總開刀數為 206 原發性肺癌 150 例，良性肺腫瘤 39 例，轉移性肺癌 17 例，而在本計劃中收案中共有 156 例包括有原發性肺癌 123 例，良性肺腫瘤 22 例，轉移性肺癌 11 例。

	原發性肺癌	良性肺腫瘤	轉移性肺癌
肺腫瘤總開刀數 206 例	150 例	39 例	17 例
本計劃收案數 156 例	123 例	22 例	11 例

依照數據分析至目前肺腫瘤總開刀數已有 206 位，但由於開刀前無法確定是否為肺癌因此需等到病理結果才能確定。而目前收案肺癌之病人達 123 位達本計畫收案數病人之 79%。值得注意的是近一年中，約有 25 例極微小(5-7mm)之肺癌，由於標本品只夠病理組織確診用，無法供本計劃使用，在未來可能用 core biopsy 取回一部份組織。



結論與建議

以 97 年 5 月-98 年 10 月收案進度分析，肺腫瘤開刀總數為 206 例，包含同意訪視問卷 178 例、同意檢體使用 170 例及病理結果符合收案條件 123 例。同時有問卷、檢體病理結果符合之收案條件為 123 例。另外加上良性個案數 22 例總共收集 145 例，受限於問卷訪視、同意檢體使用、及符合收案條件及病理結果，目前在同意收案人數約為總開刀的 76%(206 例中佔 156 例)，未來將更努力提高同意問卷訪視與檢體使用人數，提高至 80%以上甚至 90%來達成目標之人數。

為提高收案病例數量：

1. 已納入本院其他胸腔外科醫師所有疑似肺腫瘤個案。為取得問卷訪視，同意書及同意檢體使用，已取得其他胸腔外科醫師共識共同幫忙完成。
2. 也曾考慮其他醫院合作(如台中榮總胸腔外科，目前聯絡中)其中困難點有：A. 尚未取得該院醫師共識了解建置肺癌組織及其臨床資訊核心的重要性及共同合作完成。
B. 需通過該院 IRB。
3. 今後對於腫瘤過小，而無法收案組織檢體病人，改用 code biopsy 取得微小組織供本計劃研究用。
4. 已加入病理診斷是 AAH(atypical adenomatous hyperplasia) 的個案，了解有關 Adenocarcinoma、BAC 及 Precursor Molecular Base。

98 年度計畫重要研究成果及對本署之具體建議

1.本計畫之新發現或新發明

在早期之肺癌開刀病人的 X-ray 或 CT 上發現有單側或雙側 GGO 的情形大多為小於 1cm 的腫瘤，由開刀後診斷有 AAH(atypical adenomatous hyperplasia)、Adenocarcinoma、BAC 及 Precursor Molecular Base，收集更多檢體樣本將有助於了解這些病理的進展情形，有助癌症研究與病人癌症的治療。

2.本計畫對民眾具教育宣導之成果

於每位病人開刀前都會有問卷訪視，藉由訪視機會教育民眾開刀前的護理，如何練習呼吸運動與提早下床的好處以及開刀後要如何傷口護理與適當運動以加強病人手術後的正確觀念。

在訪視與問卷中若發現民眾有癌症家族史，則會主動提醒其他家屬應每年施行定期健康檢查與低劑量電腦斷層，並告知相關肺癌復發之機率，與定時回診追蹤的重要性。讓更多民眾能早期發現早期治療以達到預防勝於治療之目的。

3.本計畫對醫藥衛生政策之具體建議

由於少部分病人在本院開刀後，至其他醫院做陸續追蹤，本計劃人員會固定的線上聯繫或電話聯絡，以掌握病人後續治療及追蹤。

由於肺癌手術後之治療及追蹤多樣及複雜，在醫療整合治療及各醫院間以後電子病歷及個人病例之建置可使癌症之治療得到適切及完整的照顧。

参考文献：

1. Mackey EA, Demiralp R, Fitzpatrick KA, Porter BJ, Wise SA, Becker PR, Greenberg RR. Quality assurance in analysis of cryogenically stored liver tissue specimens from the NIST National Biomonitoring Specimen Bank (NBSB). *Sci Total Environ* 1999; 226(2-3): 165-76.
2. Tomford WW, Mankin HJ. Bone banking. Update on methods and materials. *Orthop Clin North Am* 1999; 30(4): 565-70.
3. McKee AC. Brain banking: basic science methods. *Alzheimer Dis Assoc Disord* 1999; 13 Suppl 1: S39-44.
4. Heck EL. Retrospective of a skin bank. *J Burn Care Rehabil.* 1999 Mar-Apr; 20(2): 103-7.
5. Iyer KR, Sinz MW. Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations. *Chem Biol Interact* 1999; 118(2): 151-69.
6. Williams MO. The regulation of human tissue in the United States: a regulatory and legislative analysis. *Food Drug Law J* 1997; 52(4): 409-28.
7. Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, Jones DA, Leachman SA. Preservation of RNA for functional Genomic studies: a multidisciplinary tumor bank protocol. *Mod Pathol* 2001; 14: 116-128.
8. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. *Proc Natl Acad Sci U S A* 2001; 98: 13790-5.
9. Chen JJ, Peck K, Hong TM, et al. Global analysis of gene expression in invasion by a lung cancer model. *Cancer Res* 2001; 61: 5223-30.
10. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. *Proc Natl Acad Sci U S A* 2001; 98: 13784-9.
11. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. *Cancer Res* 2002; 62: 3005-8.
12. Beer DG, Kardina SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. *Nat Med* 2002; 8: 816-24.
13. Oosterhuis JW, Coebergh JW, van Veen EB. Tumour banks: well-guarded treasures in the interest of patients. *Nat Rev Cancer.* 2003; 3: 73-7
14. Ramaswamy S. Translating Cancer Genomics into Clinical Oncology. *N Engl J Med* 2004; 350: 1814-6.
15. Wang C-C, Tsai M-F, Hong T-M, et al. The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. *Oncogene* 2005; 24: 4081-93.
16. Morrin H, Gunningham S, Currie M, Dachs G, Fox S, Robinson B. The Christchurch Tissue Bank to support cancer research. *N Z Med J.* 2005 Nov 11; 118(1225): U1735.
17. Morente MM, Alonso S. Current challenges of human tumour banking. *Hematol Oncol.* 2005 Jun; 23(2): 54-6.
18. Pitchers M, Stokes A, Lonsdale R, Premachandra DJ, Edwards DR. Research tissue banking in otolaryngology: organization, methods and uses, with reference to practical, ethical and legal issues. *J Laryngol Otol.* 2006 ; 120: 433-8.
19. Snell L, Watson PH. Breast tissue banking: collection, handling, storage, and release of tissue for breast cancer research. *Methods Mol Med.* 2006; 120: 3-24
20. Morente M. Tumour banks network: the Spanish model. *Med Sci (Paris).* 2006; 22

Spec No 1:32-4

21. Galvan R, Briseño R, Alvarez E, de la Garza C. Tissue banking in Mexico. *Cell Tissue Bank*. 2006; 7: 215-20.
22. Becker PR, Wise SA. The U.S. National biomonitoring specimen bank and the marine environmental specimen bank. *J Environ Monit*. 2006; 8: 795-9.
23. Asslaber M, Abuja PM, Stark K, Eder J, Gottweis H, Trauner M, Samonigg H, Mischinger HJ, Schippinger W, Berghold A, Denk H, Zatloukal K. The Genome Austria Tissue Bank (GATiB). *Pathobiology*. 2007; 74: 251-8.
24. Perl DP. The role of the pathologist in translational and personalized medicine. *Mt Sinai J Med*. 2007; 74: 22-6.
25. Graziano A, Biunno I, De Blasio P, Giordano A. The tissue banking in cancer and stem cell research. *J Cell Physiol*. 2007; 212: 345-7.
26. Mager SR, Oomen MH, Morente MM, Ratcliffe C, Knox K, Kerr DJ, Pezzella F, Riegman PH. Standard operating procedure for the collection of fresh frozen tissue samples. *Eur J Cancer*. 2007 ; 43: 828-34.

附錄一；空白研究調查問卷

個案編號：□□□□-□□□□-□□□□

個案姓名：_____

建置肺癌組織及其臨床資訊核心 男性危險因子問卷

國家衛生研究院
臺大醫院
林口長庚醫院
中國醫藥大學附設醫院
高雄醫學大學附設醫院

臺灣大學公共衛生學院
台北榮民總醫院
台中榮民總醫院
成功大學附設醫院

個案姓名： _____
病歷號碼： _____

身份證字號： □□□□□□□□□□

通訊電話： _____ 手機號碼： _____

通訊住址： _____

訪視者姓名： _____

訪談地點：1. 臺大醫院
2. 臺北榮民總醫院
3. 林口長庚醫院
4. 臺中榮民總醫院
5. 中國醫藥大學附屬醫院
6. 成功大學附設醫院
7. 高雄醫學大學附設醫院

訪談日期：民國□□□年□□月□□日□□時□□分

是否由家屬代答：1. 是 2. 否

代答家屬與個案的關係：1. 配偶
2. 父母
3. 兄弟姐妹
4. 子女
5. 其它（請註明） _____

請仔細閱讀作答指引

1. 除非題目有聲明，否則每題只允許一個答案。
2. 所有有關時間的資料，請以民國為單位。
3. 請注意，若題目告知您需要跳答，請依題意進行。
4. 若您覺得本問卷有任何需要改進之處，可盡量寫下您的建議，以供我們參考改進。

想請教您的背景資料

1. 您今年幾歲？ □□□歲

2. 您生日是何年何月何日？

1. 民國前

2. 民國 □□□年□□月□□日



2-1.

1. 農曆

2. 國曆

3. 血型： 1. A型 2. B型 3. AB型 4. O型 9. 不詳

4. 您上學唸書最高唸到那一個階段？

1. 未正式上學(識字班)

2. 小學

3. 國中

4. 高中或高職

5. 專科或大學

6. 研究所以上

5. 請問您從以前到現在，從事最久的一份工作是： _____

5-1. 從事最久的一份工作的時間是多久？ □□□年

6. 請問您是否曾從事過廚師的工作？

1. 是 (從事多久？□□□年)

2. 否

7. 目前婚姻狀況：1. 已婚 2. 鰥(寡) 3. 離婚或分居 4. 未婚

8. 您目前身高多少公分？ □□□公分

9. 您目前體重多少公斤？ □□□公斤

10. 請問您在確定診斷之前平常維持的體重是多少公斤(或是健康時的體重)？ □□□公斤

10-1. 您這輩子最重時的體重是多少公斤？ □□□公斤

11. 您的父親籍貫屬於哪裡？

1. 原住民

2. 本省人(河洛人，講台語)

3. 客家人

4. 外省人

5. 其他(請註明) _____

9. 不詳

12. 您的母親籍貫屬於哪裡？

- 1. 原住民
- 2. 本省人（河洛人，會講台語）
- 3. 客家人
- 4. 外省人
- 5. 其他（請註明）_____
- 9. 不詳

13.

13-1.

13-2.

想請教您有關**吸菸**的問題

14. 您是否曾經有規律地吸菸超過六個月以上？

- 1. 是（您幾歲開始有吸菸習慣？ □□□歲）
- 2. 否（若答否，請跳答第19題）

15. 現在是否已戒菸超過六個月？

- 1. 是（您幾歲戒除吸菸的習慣？ □□□歲）
- 2. 否

16. 您有規律地吸菸習慣共持續幾年？ □□□年（若曾戒過菸請扣除其戒菸時間）

17. 在您有吸菸習慣的期間內，您平均一天吸幾支菸？ □□□支數/天（一包菸20支）

18. 請問您吸菸時吸入的深度？

- 1. 吸進肺部
- 2. 吸入口腔即吐出

想請教您有關**二手菸暴露**的問題

19. 您的父親是否在您的旁邊吸菸？

- 1. 是
- 2. 否（若答否，請跳答第22題）
- 9. 不知（若不知，請跳答第22題）

20. 您的父親在您的旁邊吸菸從您□□□歲開始至□□□歲終止（共□□□年）

21. 您的父親一天吸幾支菸？ □□□支數/天

22.

23.

24.

25. 您的配偶是否在您的旁邊吸菸？（若未婚，請跳答28題）

- 1. 是
- 2. 否（若答否，請跳答第28題）
- 9. 不知（若不知，請跳答第28題）

26. 您的配偶在您的旁邊吸菸從您□□□歲開始至□□□歲終止 (共□□□年)

27. 您的配偶一天吸幾支菸? □□□支數/天

28. 請問您除了上述親人之外還有其他親友在您旁邊吸菸嗎?

- 1. 是 (大概有幾位親友在您旁邊吸菸? □□□人在這樣的環境有幾年? □□□年)
 2. 否

29. 從您以前到現在的工作環境中, 是否碰過同事在您旁邊吸菸?

1. 是 → (大概有幾位同事在您旁邊吸菸? □□□人暴露在這樣的工作環境有幾年? □□□年)
 2. 否

30.

31.

想請教您有關拜香暴露的問題

32. 請問您平均多久燒香一次?

0. 無燒香 (若答無, 請跳答第34題)
 1. 每天
 2. 每星期
 3. 每月
- 次

33. 請問您最常暴露到那一類型的香?

1. 拜香
 2. 檀香粉
 3. 香環
 4. 其他 (請註明) _____

想請教您有關空氣污染的問題

34. 請問您是否曾經每星期至少三天規律騎摩托車達六個月以上?

1. 是 → (騎摩托車騎幾年了? □□□年
每天平均騎摩托車在戶外的時間大概是多長? □□□分鐘/天)
 2. 否

想請教您過去病史及用藥史

35. 請問您曾被西醫診斷肺結核而且建議吃藥治療嗎?

1. 是 (診斷醫院 _____ ; 診斷時年齡□□□歲)
 2. 否 (若答否, 請跳答第37題)
 9. 不知

36. 請問您是否有實際接受肺結核藥物的治療?

1. 是

- 2. 否
- 9. 不知

37. 請問您是否曾被西醫診斷為肺氣腫或慢性支氣管炎？

- 1. 是(診斷醫院 _____ ; 診斷時年齡□□□歲)
- 2. 否
- 9. 不知

個案編號：□□□□-□□□□-□□□□

個案姓名：_____

建置肺癌組織及其臨床資訊核心 女性危險因子問卷

國家衛生研究院
臺大醫院
林口長庚醫院
中國醫藥大學附設醫院
高雄醫學大學附設醫院

臺灣大學公共衛生學院
台北榮民總醫院
台中榮民總醫院
成功大學附設醫院

個案姓名： _____
病歷號碼： _____

身份證字號： □□□□□□□□□□

通訊電話： _____ 手機號碼： _____

通訊住址： _____

訪視者姓名： _____

訪談地點：1. 臺大醫院
3. 林口長庚醫院
5. 中國醫藥大學附屬醫院
7. 高雄醫學大學附設醫院
2. 臺北榮民總醫院
4. 臺中榮民總醫院
6. 成功大學附設醫院

訪談日期：民國□□□年□□月□□日□□時□□分

是否由家屬代答：1. 是 2. 否

代答家屬與個案的關係：1. 配偶
2. 父母
3. 兄弟姐妹
4. 子女
5. 其它（請註明） _____

請仔細閱讀作答指引

5. 除非題目有聲明，否則每題只允許一個答案。
6. 所有有關時間的資料，請以民國為單位。
7. 請注意，若題目告知您需要跳答，請依題意進行。
8. 若您覺得本問卷有任何需要改進之處，可盡量寫下您的建議，以供我們參考改進。

想請教您的背景資料

2. 您今年幾歲？ □□□歲

2. 您生日是何年何月何日？

1. 民國前

2. 民國 □□□年□□月□□日



2-1.

1. 農曆

2. 國曆

3. 血型： 1. A型 2. B型 3. AB型 4. O型 9. 不詳

4. 您上學唸書最高唸到那一個階段？

1. 未正式上學(識字班)

2. 小學

3. 國中

4. 高中或高職

5. 專科或大學

6. 研究所以上

5. 請問您從以前到現在，從事最久的一份工作是： _____

5-1. 從事最久的一份工作的時間是多久？ □□□年

6. 請問您是否曾從事過廚師的工作？

1. 是 (從事多久？ □□□年)

2. 否

7. 目前婚姻狀況： 1. 已婚 2. 鰥(寡) 3. 離婚或分居 4. 未婚

8. 您目前身高多少公分？ □□□公分

9. 您目前體重多少公斤？ □□□公斤

10. 請問您在確定診斷之前平常維持的體重是多少公斤(或是健康時的體重)？ □□□公斤

10-1. 您這輩子最重時的體重是多少公斤(不包含懷孕)？ □□□公斤

11. 您的父親籍貫屬於哪裡？

1. 原住民

2. 本省人(河洛人，講台語)

3. 客家人

4. 外省人

5. 其他(請註明) _____

9. 不詳

12. 您的母親籍貫屬於哪裡？

- 1. 原住民
- 2. 本省人 (河洛人, 會講台語)
- 3. 客家人
- 4. 外省人
- 5. 其他 (請註明) _____
- 9. 不詳

13.

13-1.

13-2.

想請教您有關吸菸的問題

14. 您是否曾經有規律地吸菸超過六個月以上？

- 1. 是 (您幾歲開始有吸菸習慣? □□□歲)
- 2. 否 (若答否, 請跳答第18題)

15. 現在是否已戒菸超過六個月？

- 1. 是 (您幾歲戒除吸菸的習慣? □□□歲)
- 2. 否

16. 您有規律地吸菸習慣共持續幾年? □□□年

(若曾戒過菸請扣除其戒菸時間)

17. 在您有吸菸習慣的期間內, 您平均一天吸幾支菸? □□□支數/天
(一包菸20支)

想請教您有關二手菸暴露的問題

18. 您的父親是否在您的旁邊吸菸？

- 1. 是
- 2. 否 (若答否, 請跳答第21題)
- 9. 不知 (若不知, 請跳答第21題)

19. 您的父親在您的旁邊吸菸從您□□□歲開始至□□□歲終止 (共□□□年)

20. 您的父親一天吸幾支菸? □□□支數/天

21.

22.

23.

24. 您的配偶是否在您的旁邊吸菸? (若未婚, 請跳答27題)

- 1. 是
- 2. 否 (若答否, 請跳答第27題)
- 9. 不知 (若不知, 請跳答第27題)

25. 您的配偶在您的旁邊吸菸從您□□□歲開始至□□□歲終止 (共□□□年)

26. 您的配偶一天吸幾支菸? □□□支數/天

27. 請問您除了上述親人之外還有其他親友在您旁邊吸菸嗎?

1. 是 (大概有幾位親友在您旁邊吸菸? □□□人在這樣的環境有幾年? □□□年)
 2. 否

28. 從您以前到現在的工作環境中, 是否碰過同事在您旁邊吸菸?

1. 是 (大概有幾位同事在您旁邊吸菸? □□□人暴露在這樣的工作環境有幾年? □□□年)
 2. 否

29.

30.

想請教您有關**油煙暴露**的問題

31. 請問您有自己持續煮食六個月嗎?

1. 是
 2. 否 (若答否, 請跳答第35題)
 9. 不知 (若不知, 請跳答第35題)

32. 請問您幾歲開始自己煮食? □□□歲

33. 請問您煮食到幾歲? □□□歲

34. 請問您煮菜時有使用排油煙機的習慣嗎?

1. 有 (幾歲開始使用? □□□歲)
 2. 否

	A. 0-20歲	B. 21-40歲	C. 41歲以上
I. 請問您平均多久煮食一次?	<input type="checkbox"/> 0. 無 <input type="checkbox"/> 1. 每天 <input type="text"/> 次 <input type="checkbox"/> 2. 每星期 <input type="text"/> 次 <input type="checkbox"/> 3. 每月 <input type="text"/> 次	<input type="checkbox"/> 0. 無 <input type="checkbox"/> 1. 每天 <input type="text"/> 次 <input type="checkbox"/> 2. 每星期 <input type="text"/> 次 <input type="checkbox"/> 3. 每月 <input type="text"/> 次	<input type="checkbox"/> 0. 無 <input type="checkbox"/> 1. 每天 <input type="text"/> 次 <input type="checkbox"/> 2. 每星期 <input type="text"/> 次 <input type="checkbox"/> 3. 每月 <input type="text"/> 次
II. 您最常用哪一種燃料來煮食?	<input type="checkbox"/> 1. 木柴或木炭 <input type="checkbox"/> 2. 生煤、煤球或煤油 <input type="checkbox"/> 3. 瓦斯(液化石油, 天然氣) <input type="checkbox"/> 4. 其他	<input type="checkbox"/> 1. 木柴或木炭 <input type="checkbox"/> 2. 生煤、煤球或煤油 <input type="checkbox"/> 3. 瓦斯(液化石油, 天然氣) <input type="checkbox"/> 4. 其他	<input type="checkbox"/> 1. 木柴或木炭 <input type="checkbox"/> 2. 生煤、煤球或煤油 <input type="checkbox"/> 3. 瓦斯(液化石油, 天然氣) <input type="checkbox"/> 4. 其他
III. 您最常用哪一種食用油煮食?	<input type="checkbox"/> 1. 動物性油 (豬油, 清香油) <input type="checkbox"/> 2. 植物性油 (大豆油, 花生油, 葵花油) <input type="checkbox"/> 3. 其他	<input type="checkbox"/> 1. 動物性油 (豬油, 清香油) <input type="checkbox"/> 2. 植物性油 (大豆油, 花生油, 葵花油) <input type="checkbox"/> 3. 其他	<input type="checkbox"/> 1. 動物性油 (豬油, 清香油) <input type="checkbox"/> 2. 植物性油 (大豆油, 花生油, 葵花油) <input type="checkbox"/> 3. 其他
IV. 請問您一星期中食物烹調習慣?			

想請教您有關拜香暴露的問題

35. 請問您平均多久燒香一次？

0. 無燒香 (若答無,請跳答第37題)
1. 每天
2. 每星期
3. 每月
- 次

36. 請問您最常暴露到那一類型的香？

1. 拜香
2. 檀香粉
3. 香環
4. 其他 (請註明) _____

想請教您有關空氣污染的問題

37. 請問您是否曾經每星期至少三天規律騎摩托車達六個月以上？

1. 是→(騎摩托車騎幾年了? 年
每天平均騎摩托車在戶外的時間大概是多長? 分鐘/天)
2. 否

想請教您月經及生育的狀況

38. 請問您第一次的月經是幾歲開始? 歲

39. 請問您長期以來的月經週期是否規則？

1. 是→請問您多久來一次月經?(大約相隔幾天?) 天
2. 否
9. 不知

40. 請問您每次月經平均來幾天? 天

41. 請問您在確定診斷前月經的情形是？

1. 仍然與長期的月經週期狀況相同 (若答1,請跳答第44題)
2. 開始不規則, 斷斷續續 → 年月開始 (若答2,請跳答第44題)
3. 停經
9. 不知

42. 若已經停經, 請問停經的原因？

1. 自然停經
2. 手術後停經
9. 其他或不知道

43. 若已經停經, 請問是幾歲停經(最後一次來月經)? 歲

44. 請問您是否曾接受過荷爾蒙補充治療？

1. 是→(幾歲開始接受荷爾蒙補充治療? 歲
接受荷爾蒙補充治療共多久? 共月)

2. 否
9. 不知

45. 請問您是否曾經懷孕過？

1. 是→(一共懷孕過幾次？ 次
第一次懷孕時幾歲？ 歲
最後一次懷孕時幾歲？ 歲)
2. 否 (若答否,請跳答第51題)
9. 不知

46. 請問您是否曾經生產過 (包括死產, 不包括流產) ?

1. 是→(曾經生產幾次？ 次
生第一胎時幾歲？ 歲
生最後一胎時幾歲？ 歲)
2. 否
9. 不知

47. 請問您是否曾經流產過 (包括自然流產及人工流產) ?

1. 是→(流產過幾次？ 次
請問您自然流產 次
請問您人工流產 次)
2. 否
9. 不知

48. 請問您曾經餵過母乳嗎？

1. 是→(餵過幾胎母乳？共胎
所有餵母乳時間共餵多久？ 月)
2. 否
9. 不知

49.
50.
51.
52.

53. 請問您是否曾接受子宮或卵巢切除手術？

	A. 是否接受手術	B. 手術年齡	C. 停經前或後手術	D. 手術原因(請註明)
I. 子宮切除手術	<input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 歲	<input type="checkbox"/> 1. 前 <input type="checkbox"/> 2. 後	
II. 卵巢切除手術	<input type="checkbox"/> 1. 是(<input type="checkbox"/> 1單 <input type="checkbox"/> 2雙 <input type="checkbox"/> 9不知)側切除 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 歲	<input type="checkbox"/> 1. 前 <input type="checkbox"/> 2. 後	

54. 請問您是否曾口服避孕藥來避孕？

1. 是(幾歲開始使用口服避孕藥？ 歲
口服避孕藥共使用多久？ 月)
2. 否
9. 不知

想請教您過去病史及用藥史

55. 請問您曾被西醫診斷肺結核而且建議吃藥治療嗎？

1. 是(診斷醫院 _____ ; 診斷年齡□□□歲)
2. 否(若答否,請跳答第57題)
9. 不知

56. 請問您是否有實際接受肺結核藥物的治療？

1. 是
2. 否
9. 不知

57. 請問您是否曾被西醫診斷為肺氣腫或慢性支氣管炎？

1. 是(診斷醫院 _____ ; 診斷年齡□□□歲)
2. 否
9. 不知

58. 請問您母親、姊妹或女兒是否曾罹患下列癌症：

	A. 乳癌	B. 卵巢癌	C. 子宮頸癌	D. 子宮內膜癌
I. 母親	<input type="checkbox"/> 1. 是(診斷年齡□□□) <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 1. 是(診斷年齡□□□) <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 1. 是(診斷年齡□□□) <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 1. 是(診斷年齡□□□) <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知
II. 姊妹	<input type="checkbox"/> 0. 無姊妹 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 0. 無姊妹 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 0. 無姊妹 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 0. 無姊妹 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知
III. 女兒	<input type="checkbox"/> 0. 無女兒 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 0. 無女兒 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 0. 無女兒 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知	<input type="checkbox"/> 0. 無女兒 <input type="checkbox"/> 1. 是 <input type="checkbox"/> 2. 否 <input type="checkbox"/> 9. 不知

個案編號：□□□□-□□□□-□□□□

個案姓名：_____

建置肺癌組織及其臨床資訊核心 家族史問卷

訪視者姓名：_____

是否由家屬代答：1. 是 2. 否

代答家屬與個案的關係：1. 配偶
2. 父母
3. 兄弟姐妹
4. 子女
5. 其它（請註明）_____

1. 您是否為雙胞胎或多胞胎之一？ 1. 是 2. 否 9. 不知

(若答否或不知, 請跳答第 5 題)

2. 與您同時出生的手足有多少位？位

3. 在這些與您同時出生的手足中，有多少位是同卵雙生？位

4. 在這些與您同時出生的手足中，有多少位是異卵雙生？位

5. 父親是否有肺癌？1. 是 2. 否 9. 不知

6. 母親是否有肺癌？1. 是 2. 否 9. 不知

7. 同父同母之兄弟共人，其中人有肺癌

8. 同父同母之姐妹共人，其中人有肺癌

9. 同父異母之兄弟共人，其中人有肺癌

10. 同父異母之姐妹共人，其中人有肺癌

11. 異父同母之兄弟共人，其中人有肺癌

12. 異父同母之姐妹共人，其中人有肺癌

13. 配偶共人（含離婚者），其中人有肺癌

14. 兒子共人，其中人有肺癌

15. 女兒共人，其中人有肺癌

16. 祖父是否有肺癌？1. 是 2. 否 9. 不知

17. 祖母是否有肺癌？1. 是 2. 否 9. 不知

18. 外祖父是否有肺癌？1. 是 2. 否 9. 不知

19. 外祖母是否有肺癌？1. 是 2. 否 9. 不知

20. 孫子共人，其中人有肺癌

21. 孫女共人，其中人有肺癌

22. 外孫子共人，其中人有肺癌

23. 外孫女共人，其中人有肺癌

24. 其他血親是否有肺癌？1. 是 _____ 2. 否 9. 不知

附錄二：Code Book

Gender :	1. Male 2. Gemale
Differentiation :	1. well 2. moderately 3. poor 4. not applicable
Staging:	pathological staging
Disease type:	1. primary lung ca 2. metastatic lung ca 3. 肺良性病變
Survival State	S: Survival D: Dead
Smoke history	1. 吸煙 2. 不吸煙 3. 曾經吸煙
Drink history	1. 喝酒 2. 不喝酒 3. 曾喝酒
Family history	1. with same site 2. with different site 3. unknown site 9. non-contributory

腫瘍編號	NIRI 腫瘍編號	病歷號	Date of birth	Gender	Age	OP date	OP site	OP type	Cell type	Differentiation	Staging	T	N	M	Disease type	Date of last F/U	Survival State
LSFC-0001-501	C5006	22281920	1947/1/10	2	61	2008/5/14	RML	Lobectomy	Adeno.	3	Ia	1	0	0	I	2009/11/4	S
LSFC-0001-503	C5007	23475584	1954/5/10	1	54	2008/5/14	LLL	Lobectomy	Adeno.	1	Ia	1	0	0	I	2009/7/6	S
LSFC-0001-500	C5008	23487345	1956/1/10	2	52	2008/5/22	LLL; LUL	lobectomy; wedge resection	SCC	2	IIb	2	1	0	I	2009/9/11	S
LSFC-0004-506	C5011	409325	1946/3/7	2	62	2008/6/4	RUL	Lobectomy	Adeno.	2	Ia	1	0	0	I	2009/11/10	S
LSMC-0005-501	C5012	23499168	1948/12/28	1	60	2008/6/19	RUL; RML	Segmental resection; Wedge resection	Adeno.	1	IV	2	x	1	I	2008/7/3	S
LSMC-0006-502	C5013	16227386	1940/12/25	1	68	2008/7/14	LUL	Lobectomy	SCC	3	IIIa	3	2	0	I	2009/10/20	S
LSMC-0007-502	C5015	394534	1932/12/7	1	76	2008/7/17	RML	Lobectomy	SCC	2	I	1	0	0	I	2009/11/16	S
LSMC-0005-503	C5017	23671866	1954/1/20	1	54	2008/7/23	RUL	Lobectomy	Adeno.	2	IIb	3	0	0	I	2009/10/19	S
LSFC-0011-504	C5019	553438	1954/1/12	1	54	2008/7/30	LLL	Lobectomy	Adeno.	1	Ia	1	0	0	I	2009/7/13	S
LSFC-0014-505	C5022	569551	1944/4/10	2	64	2008/8/4	LUL	Lobectomy	Adeno.	2	Ia	1	0	0	I	2009/11/16	S
LSFC-0015-504	C5023	314294	1948/9/8	2	60	2008/8/6	LUL	Lobectomy	Adeno.	2	IIIa	2	2	0	I	2009/11/12	S
LSFC-0016-503	C5024	23640785	1967/10/17	2	41	2008/9/1	RUL; RUL; RML	lobectomy;wedge	Adenosquamous	未描述	VI	4	2	1	I	2008/12/18	D
LSFC-0017-503	C5025	23740185	1930/4/11	2	2	2008/9/1	RML	wedge	Adeno.	2	Ib	2	0	0	I	2009/10/19	S
LSFC-0019-503	C5027	23871906	1938/9/7	2	70	2008/9/3	RLL	lobectomy	Adeno.	2	Ib	2	0	0	I	2009/11/5	S
LSFC-0020-503	C5028	980914	1942/6/5	2	66	2008/9/3	LUL	wedge	Adeno.	1	IIIa	2	2	0	I	2009/10/20	S
LSFC-0021-501	C5029	17897053	1948/9/16	2	60	2008/9/4	RUL	Lobectomy	Adeno.	2	IIIa	3	2	0	I	2009/10/2	S
LSMC-0022-502	C5030	23943452	1957/9/16	1	51	2008/9/10	RUL	Lobectomy	Adeno.	2	IIb	2	1	0	I	2009/11/4	S
LSFC-0022-504	C5031	11539953	1948/8/16	2	60	2008/10/1	RLL	lobectomy	Adeno.	2	IIA	1	1	0	I	2009/11/16	S
LSMC-0026-501	C5034	16302484	1941/6/22	1	67	2008/10/1	RUL	lobectomy	Adeno.	1	Ia	1	0	0	I	2009/9/17	S
LSFC-0028-503	C5036	23382921	1950/12/10	2	57	2008/10/8	LUL	lobectomy	Adeno.	1	Ia	1	0	0	I	2009/7/31	S
LSFC-0028-502	C5037	11192139	1949/2/21	2	59	2008/10/8	RML	lobectomy	Adenosquamous	1	Ia	1	0	0	I	2008/10/20	S
LSFC-0030-508	C5038	23990912	1936/5/25	2	72	2008/10/15	RLL	lobectomy	Adeno.	1	IIIb	4	0	0	I	2009/7/13	S
LSMC-0031-501	C5039	23206112	1925/1/20	1	82	2008/10/15	RLL	Lobectomy	Adeno.	2	IIIa	2	2	0	I	2009/7/1	D
LSMC-0033-504	C5041	787992	1934/4/25	1	74	2008/10/22	RLL	lobectomy	SCC	2,J	IIIb	2	1	0	I	2009/4/28	S
LSMC-0034-501	C5042	16351629	1926/1/27	1	81	2008/10/22	RUL	wedge resection	BAC	1	Ia	1	0	0	I	2009/11/9	S
LSFC-0035-501	C5043	11905	1948/4/16	2	60	2008/10/29	LLL	lobectomy	BAC	1	Ia	1	0	0	I	2009/7/27	S

編號	NHRI 檢體編號	所屬院	Date of Death	Survival (day)	s/p op therapy	History	s/p OP	Metast site	Metast date	Recurrence site	Recurrence date	Smoke history	Drink history	Family history	Delayed Dx	GGO (+)	備註	multiple primary
L5FC-002-501	C5006	22281920		530	ST	1. with a history of HTN, MVP, adenocarcinoma adenocarcinoma stage IIIb s/p Tarexva. On 2008/04/30, there is a						2	2	9				
L5FC-001-503	C5007	23475584		412		1. with a history of hypertension, GERD.						2	2	9	+			
L5FC-003-500	C5008	23487345		469								2	2	9				
L5FC-004-506	C5011	409325		516	CT	1. with a history of HTN, MVP.						2	2	9	+			
L5MC-005-501	C5012	23499168		14		appendicitis s/p surgery 30 years ago						3	1	9			9705 備中藥退藥出藥 目前吃RESSA 2009/11/11 F/u	
L5MC-006-502	C5013	16227386		456	CT	1. with a history of LLL lung cancer (NSCLC, preferred SCC) and gastric CA s/p OP.						3	2	9				
L5MC-007-502	C5015	394534		479	a/fur	1. with histories of DU/GU and HTN.						1	2	9				
L5MC-009-503	C5017	23671866		446	CT+elbr							2	1	9		+		
L5FC-011-504	C5019	553438		343								2	2	9		+		
L5FC-014-505	C5022	569551		462								2	2	3				
L5FC-015-504	C5023	324284		456	2009/11/5 TRESSA							2	2	9		+		
L5FC-016-503	C5024	23640785	98年過世	107		nil	nil	RUL	2009/9/11			2	2	9				
L5FC-017-503	C5025	23740185		408		nil	nil					2	2	9				
L5FC-019-503	C5027	23871906		422		nil	nil	brain	2009/9/20			2	2	9				
L5FC-020-503	C5028	980914		417		nil	nil					2	2	9		+		
L5FC-021-501	C5029	17897653		388	CCRT	adenocarcinoma cancer s/p op 5 years ago HTN under medical control	nil					2	2	9				
L5MC-022-502	C5030	23943452		414	CT	nil	nil					2	2	9				
L5FC-023-504	C5031	11539953		405	CT later	HTN with medical control for 2 years Stress urinary incontinence s/p operation 7-8 years ago	nil					2	2	9		+		
L5MC-023-501	C5034	16302484		346	2009/02/2 heart abt	Hypertension	nil					2	2	9				
L5FC-028-503	C5036	23383221		293		cholecystectomy 4 years ago	nil					2	2	2		++	F/u 2009/11/3 痰台藥 備追錄	+
L5FC-028-502	C5037	11192139		22		nil	nil					2	2	2		++	F/u 2009/10/6 痰台藥 備追錄	+
L5FC-030-508	C5038	2399542		268		HTN under regular medical control 2/ Drops TB, DM or other systemic disease 3) Peptic ulcer and angina	nil					2	2	9		++		+
L5MC-031-501	C5039	23296112	2009/07/17 元 出產	256		nil	nil					3	2	9				
L5MC-033-504	C5041	787892		178	CCRT	1. Hepatoma s/p resection 2. Splenic stenosis s/p op	nil	lung and LN metastasis	2009/5/18			2	2	9				
L5MC-034-501	C5042	1631629		377	2009/2/12 after	HTN, RML adenocarcinoma s/p lobectomy, BPH s/p TUR-P-peptic ulcer, LLL bronchiolar carcinoma s/p LLL lobectomy	nil					2	2	9		++	multiple metastases cancer of lung 90.95.97 RML, LLL, RUL	+
L5FC-035-501	C5043	11905		268		nil	nil					2	2	9		++		

編號	NHRI 檢體編號	序號	Date of birth	Gender	Age	OP date	OP site	OP type	Cell type	Differentiation	Staging	T	N	M	Disease type	Date of last F/U	Survival Status
L5FC-0028-501	C50044	1797284	1947/1/1	2	61	2008/10/22	LLL	lobectomy	BAC	1	Ia	1	0	0	I	2008/11/13	S
L5FC-0037-504	C50045	11479720	1969/1/08	1	39	2008/10/23	RUL	Lobectomy	BAC/AAH	1	Ia	1	0	0	I	2009/11/16	S
L5FC-0016-502	C50024-2	23440785	1967/10/17	2	42	2008/10/27	right ribs and chest wall	Eisner's flap with open drainage and chest wall resection	Adenoquamous		IIIB	4	3	0	I	2008/12/18	D
L5MC-0039-502	C50047	24014809	1957/4/1	1	51	2008/10/29	LUL	lobectomy	Adeno.	1	Ia	1	0	0	I	2009/10/8	S
L5MC-0042-501	C50050	24014590	1946/12/15	1	61	2008/11/12	RUL	lobectomy	BAC	1	Ia	1	0	0	I	2009/8/24	S
L5MC-0045-508	C50053	856134	1931/7/1	1	77	2008/11/12	LJUL	wedge resection	Adeno.	3	Ia	1	0	0	I	2009/10/29	S
L5FC-0046-504	C50054	23999717	1938/6/14	2	70	2008/11/12	LUL	lobectomy	Adeno.	2	Ia	1	0	0	I	2009/7/16	S
L5MC-0047-504	C50055	23983105	1952/4/15	1	56	2008/11/12	LLL	lobectomy	Adeno.	2	IIIA	2	2	0	I	2009/10/22	S
L5MC-0057-506	C50057	24069144	1943/12/27	1	64	2008/11/19	LUL	lobectomy	Adeno.	2	Ia	1	0	0	I	2009/10/16	S
L5MC-0058-503	C50058	827772	1934/1/10	1	74	2008/11/19	LUL	lobectomy	Adeno.	2	IIIA	2	0	0	I	2009/11/12	S
L5MC-0059-501	C50059	24043624	1946/6/14	1	62	2008/12/2	RML/RLL	Bilectomy	SCC	2	IIIA	3	2	0	I	2009/4/11	S
L5MC-0061-501	C50061	12883264	1925/11/27	1	83	2008/12/3	LUL	segmentectomy	stromaloid carcinoma	4	Ib	2	0	0	I	2009/10/29	S
L5MC-0062-501	C50062	19791388	1927/11/13	1	81	2008/12/3	RLL	Lobectomy	Adeno.	2	IIIA	2	2	0	I	2009/10/28	S
L5MC-0063-502	C50063	24102448	1947/9/20	1	61	2008/12/10	RUL	lobectomy	Adeno.	1	Ia	2	0	0	I	2009/11/2	S
L5FC-0064-502	C50064	24086917	1960/1/20	2	48	2008/12/10	RL	lobectomy	Adeno.	1	Ia	1	0	0	I	2009/7/10	S
L5FC-0065-503	C50065	949239	1960/6/2	2	48	2008/12/10	RUL	lobectomy	Adeno.	2	Ia	1	0	0	I	2009/8/27	S
L5FC-0066-505	C50066	24102837	1940/6/27	2	68	2008/12/17	RL/RUL	lobectomy/wedge resection	BAC/epithelial carcinoma	未描述	Ia	1	0	0	I	2009/8/24	S
L5MC-0067-501	C50067	23877322	1930/3/3	1	78	2008/12/24	RUL	wedge resection	SCC non-keratinizing	2	Ia	1	0	0	I	2009/7/16	S
L5FC-0068-504	C50068	24037647	1948/2/29	2	60	2008/12/24	RUL	lobectomy	Adeno.	2	Ia	1	0	0	I	2009/11/9	S
L5MC-0069-501	C50069	23944250	1955/2/15	1	53	2008/12/24	LLL/LUL	lobectomy / wedge resection	SCC non-keratinizing/organize of carcinoma	3	Ia	1	0	0	I	2009/11/12	S
L5MC-0070-503	C50070	24120977	1945/9/20	1	63	2008/12/24	RUL	lobectomy	Adeno.	2	Ib	1	0	0	I	2009/8/31	S
L5MC-0071-504	C50071	405576	1947/9/4	1	61	2008/12/29	RLL	lobectomy	adenosquamous	未描述	IIIA	3	2	0	I	2009/2/12	S
L5FC-0044-506	C50052-2	23983341	1949/7/1	2	60	2009/1/8	LUL	lobectomy	Adeno.	2	IV	4	1	1	I	2009/11/6	S
L5FC-0072-501	C50072	11308183	1947/11/16	2	61	2009/1/7	LUL	lobectomy	Adeno.	1	Ia	1	0	0	I	2009/10/26	S
L5MC-0073-504	C50073	21378871	1959/1/13	1	50	2009/1/7	LLL	lobectomy	Adeno.	2	IIa	1	1	0	I	2009/10/29	S
L5MC-0074-502	C50074	21894671	1953/2/3	1	54	2009/1/7	LUL	lobectomy	BAC	1	Ia	1	0	0	I	2009/1/8	S

個案編號	NBR/檢體編號	病歷號	Date of Death	Survival (day)	Age at death	History	Site of OP	Meta site	Meta date	Recurrence site	Recurrence date	Smoke history	Drunk history	Family history	Deceased Dx	GGO (+)	備註	multiple primary
LSFC-0025-501	C50644	17497284		21	21	appendectomy 4yrs ago	nil					2	2	9		++	Flu, 2009/11/18 在中 藥總匯買肉乾吃 HESSA	
LSFC-0037-504	C50645	11479720		383	383	Endometriosis	nil					2	2	9		++	左側頸部 GGO 三劑 BAC AAH AAH	+
LSFC-0016-502	C50642-2	23440785	99年過世	51	51	nil	nil	RUL	2006/9/11			2	2	9		++		
LSMC-0039-502	C50647	24014809		339	339	1.Past Medical History GU of 10 years allergy rhinitis for 30 years	nil					2	2	9		++		
LSMC-0042-501	C50650	24014590		202	202	nil	nil					2	2	9		++		
LSMC-0045-508	C50653	856134		347	347	nil X-ray cause remnant TCC, lung cancer, NSCLC TIN040 stage IA, Diabetes mellitus Type II HTN	nil					1	1	9				+
LSFC-0046-504	C50654	23999717		244	244	allergic rhinitis, asthma and HTN	nil	left pleural	2009/8/6	left pleural	2009/7/30	2	2	9			癌台結核菌氣腫	
LSMC-0047-504	C50655	23983105		340	340	HTN controlled through Atenolol	nil					3	3	9		++		
LSMC-0057-506	C50657	24069144		327	327	nil	nil					3	1	9		++		
LSMC-0058-503	C50658	827772		353	2008/12/1 start after	1.Lung cancer in 95.03 2.IV-CAD SP PCL	nil					2	2	9		++		
LSMC-0059-501	C50659	24043624		129	129	1.Lung cancer in 95.03 2.IV-CAD SP PCL	nil					1	2	9		+		
LSMC-0061-501	C50661	12883264		326	326	1. HTN, gout 2. nasal polyps 3. hemorrhoid	prostate enlargement s/p op					1	2	9				
LSMC-0062-501	C50662	19791388		325	2005/2/26 start CT to 2009/3/9 nil this time) no diet control nil G C208	1. hyperostrophy (osteophyte) prostate with urine retention, bladder stones/ p KTP laser	nil					1	1	9				
LSMC-0063-502	C50663	24102448		322	2009/1/19 start UFUR	1) hypertension (irregularly) 2) BPH, under medical treatment	nil					1	1	9				
LSFC-0064-502	C50664	24086937		210	210	1. fatty liver 2. HBV	1. right breast cancer, infiltrating ductal carcinoma, Nuclear grade 1					2	2	9				
LSFC-0065-503	C50665	949239		257	257	nil	hypertension 13 years ago 2. thyroiditis s/p T4/T4					2	2	9				
LSFC-0066-505	C50666	24102837		247	247	angia	nil					2	2	9		++		
LSMC-0067-501	C50667	23877322		202	202	COPD	nil					1	1	9				
LSFC-0068-504	C50668	24037647		315	315	nil	nil					2	2	9				
LSMC-0069-501	C50669	23944250		318	318	1. thyroiditis 2. chronic airway obstruction, not elsewhere classified	nil					1	1	9				
LSMC-0070-503	C50670	24120977		247	247	1. Old MI	nil					2	1	9		+		
LSMC-0071-504	C50671	405276		43	43	Past Medical History: 1) asthma 2) hypertension 3) CT 33 cycles (P11)	nil					2	2	9				
LSFC-0044-506	C50653-2	23983341		298	207/2026 in 216A	nil	right upper lobe organizing pneumonia s/p wedge resection.					2	2	9		+		
LSFC-0072-501	C50672	11308183		289	289	panic disorder under Xanax treatment	CIS s/p conization 8 years ago					2	2	9		+		
LSMC-0073-504	C50673	21378871		292	NI-S18 G-C A33	Hyperostosis Dyslipidemia	TIN040, stage 1 s/p wedge resection					1	1	9		+		
LSMC-0074-502	C50674	21894671		271	271	nil	retinal defect, unspecified, s/p operation 2 years ago					3	1	3		+		

個案編號	NERI 檢體編號	病歷號	出生日期	Gender	Age	OP date	OP site	OP type	Cell type	Differentiation	Staging	T	N	M	Diastase type	Date of last FU	Survival State
LSFC-0075-502	C50075	13648958	1942/2/12	2	66	2009/1/15	RUL/RML	segmental resection	secretory glandular inflammation							2009/8/6	S
LSMC-0076-503	C50076	19331660	1936/10/23	1	72	2009/1/14	RUL	wedge resection	SCC, non-keratinizing	3	IIa	2	0	0	I	2009/1/12	S
LSFC-0077-501	C50077	24170814	1948/02/10	2	60	2009/2/4	LLL	lobectomy	Adeno.	2	IIIa	2	2	0	I	2009/10/26	S
LSMC-0078-504	C50078	628186	1949/10/24	1	59	2009/2/14	RUL	segmental resection	BAC non-mucinous	1	Ia	1	0	0	I	2009/10/12	S
LSMC-0079-501	C50079	12334210	1956/01/14	1	52	2009/2/11	LLL	wedge resection	organizing pneumonia						S	2009/8/3	S
LSMC-0080-502	C50080	752105	1940/1/15	1	68	2009/2/11	RML	Wedge resection	Adeno.	2,3	Ia	1	0	0	I	2009/1/12	S
LSFC-0081-504	C50081	24866820	1958/5/19	2	50	2009/2/11	RUL	wedge resection/lobectomy	Adeno.	2	Ia	1	0	0	I	2009/7/20	S
LSFC-0082-504	C50082	23694055	1971/1/13	2	38	2009/2/18	LLL	wedge resection	BAC, non-mucinous	1	Ia	1	0	0	I	2009/8/26	S
LSFC-0083-501	C50083	787893	1966/4/20	2	42	2009/2/18	LLL	wedge resection	focal type II pneumocyte hyperplasia						S	2009/6/25	S
LSMC-0084-506	C50084	24286939	1937/12/10	1	71	2009/2/18	LLL	wedge resection	Adeno.	3	IIa	2	0	0	I	2009/1/19	S
LSMC-0085-502	C50085	24184513	1940/0/15	1	68	2009/2/18	RUL/RML	bisectomy	lymphoepithelioma-like carcinoma	3,5	IIIb	2	1	0	I	2009/9/28	S
LSMC-0086-502	C50086	24191867	1937/5/13	1	71	2009/2/25	LLL	lobectomy	Adeno.	2	Ia	1	0	0	I	2009/1/12	S
LSMC-0087-501	C50087	24065817	1967/1/18	1	42	2009/2/25	RUL	lobectomy	Adeno.	3	Ib	2	0	0	I	2009/1/12	S
LSMC-0088-502	C50088	594689	1954/4/23	1	54	2009/3/5	LLL	lobectomy	BAC, non-mucinous type	1	Ia	1	0	0	I	2009/10/30	S
LSFC-0089-503	C50089	24322019	1993/7/7	2	15	2009/3/4	LLL	lobectomy	inflammatory myofibroblastic tumor						S	2009/6/25	S
LSFC-0090-507	C50090	24184860	1944/2/1	2	65	2009/3/11	RUL	wedge resection	foreign body granuloma						S	2009/6/15	S
LSFC-0091-503	C50091	23679326	1954/1/19	2	54	2009/3/11	RUL/RML/LLL	segmental resection/wedge resection	adeno. /squamous/AAH	2	Ia	1	0	0	I	2009/8/31	S
LSFC-0092-501	C50092	24323039	1966/8/1	2	42	2009/3/18	LLL	wedge resection	ulcerating hemangioma						S	2009/4/6	S
LSFC-0093-501	C50093	426012	1949/4/20	2	59	2009/3/11	LUL	segmental resection	BAC	1	Ia	1	0	0	I	2009/1/15	S
LSMC-0094-501	C50094	698687	1936/11/27	1	72	2009/3/19	LLL	lobectomy	SCC, non-keratinizing	2	Ia	1	0	0	I	2009/10/26	S
LSFC-0095-501	C50095	566381	1961/1/6	2	48	2009/3/23	RUL	lobectomy	Adeno.	2	Ia	1	0	0	I	2009/1/15	S
LSMC-0096-503	C50096	448569	1938/10/15	1	70	2009/3/25	RUL	lobectomy	Adeno.+BAC	1	Ia	1	0	0	I	2009/7/9	S
LSFC-0097-505	C50097	608990	1931/9/10	2	77	2009/3/25	RUL	lobectomy	Adeno.	1,2	IIIa	4	0	0	I	2009/10/27	D
LSMC-0098-503	C50098	15347396	1954/3/26	1	55	2009/4/1	LUL	wedge resection	Adeno. Metastatic (from colon)	2					2	2009/9/18	S
LSMC-0099-507	C50099	16511207	1951/1/15	1	58	2009/4/1	RUL	lobectomy	Adeno.	2	I	X	0	X	I	2009/5/4	*
LSMC-0100-502	C50100	23109470	1963/10/28	1	47	2009/4/6	LUL	wedge resection	granulomatous inflammation	1					5	2009/10/22	S

編號	NHRI 核准編號	病歷號	Date of Death	Survival (day)	Up OP therapy	History	Up OP	Meta site	Recurrence site	Recurrence date	Smoke history	Drink history	Family history	Delayed Dx	GGO (+)	備註	multiple primary
L5FC-0075-502	C50075	13449958		261		hypertension	gastrostomy due to GU bleeding				2	2	9				
L5MC-0076-503	C50076	19331660		288		-DM type II -paraphimosis w/p circumcision -progressive bilateral hearing loss	right buccal Ca, T2NM0 w/p radical op + PMMCF reconstruction				1	1	9				
L5FC-0077-501	C50077	24178814		262		nil	nil				2	2	9				
L5MC-0078-504	C50078	628186		248		nil	solitary lymphangoma of the lung w/p RUL wedge resection				2	2	9				
L5MC-0079-501	C50079	12334210		172		HTN	solitary lymphangoma of the lung w/p RUL wedge resection (T2NM0) w/p major vein v/u embolization (P110R3)				3	2	9				
L5FC-0080-502	C50080	752185		261		nil	94年因 VGHTC: ca of lung post lobectomy, stage T2NM0				2	2	9				
L5FC-0081-504	C50081	24666820		159		nil	nil				3	2	9				
L5FC-0082-504	C50082	23694055		188		1. Chronic hepatitis B 2. thyroid disorder: autoimmune thyroid disease Multiple nodular goiter	nil				2	2	9		+		
L5FC-0083-501	C50083	787793		127		1. current smoker: hypertension, regular smoker up in one OPD for 5+ years 2. total hip joint	nil				2	2	9		+		
L5MC-0084-506	C50084	24206939		261		hypertension duodenal ulcer urethral stone	lung cancer w/p right lobectomy 7 years ago				3	2	9		+		
L5MC-0085-502	C50085	24184513		220		nil	Lipoma w/p.				1	1	9				
L5MC-0086-502	C50086	24191867		247		1. Coronary artery disease: under treatment control 2. Lacunar infarction, can perform daily life now	Renal stone w/p URSL(ESWL)				2	2	9		+		
L5MC-0087-501	C50087	24665817		247		HTN for 4-5 years, under medication, control 120-130/90	nil				2	2	3		+		
L5MC-0088-502	C50088	594689		235		2) Hypothyroidism due to RT 3) IDA 4) C6/C7 HYD	1) Cervical intraosseous tumor w/p CRT & CGRT 2) Intestinal obstruction w/p op				3	1	9		+		
L5FC-0089-503	C50089	24322019		111		nil	nil				2	2	9				
L5FC-0090-507	C50090	24184660		94		nil	10+ years ago 氣胸刀 at VGHTC				2	2	9				
L5FC-0091-503	C50091	23679326		170		hypertension	w/p resection reaction to RUL of lung, wedge resection of lung				2	2	9		+		
L5FC-0092-501	C50092	24322039		19		nil	nil				2	2	9				
L5FC-0093-501	C50093	426612		239		nil	1. Colon polyp, w/p colonoscopy and polypectomy. 2. Chronic duodenal ulcer, w/p				2	2	9		+		
L5MC-0094-501	C50094	696687		221		nil	anal fistula w/p op				1	1	9		+		
L5FC-0095-501	C50095	566381		227		nil	nil				2	2	3		+		
L5MC-0096-503	C50096	440569		106		hypertension, under medication, w/p aspirin 100mg, bisoprolol 5 mg, metoprolol 20mg, and atorvastatin 5mg	2. Hemorrhoid w/p surgery 10+ years ago				2	2	9		+		
L5FC-0097-505	C50097	648990	2009/10/26	216		1. Chronic kidney disease, stage 4 2. B-II anatomical ulcer	calculi of gallbladder with acute cholecystitis with obstruction w/p PTCD				1	2	9		+		
L5MC-0098-503	C50098	15347396		170		DM for 8-9 years, under medical control HTN for 3-4 years, under medical control	w/p resection reaction to metastasis, w/p anterior low				2	2	9				
L5MC-0099-507	C50099	16511207		33		rectal cancer	rectal cancer w/p op and chemotherapy on 1998/7				2	2	9				
L5MC-0100-502	C50100	23109470		199		nil	nil				2	2	9				

個案編號	NERI 治療編號	病歷號	Date of birth	Gender	Age	OP date	OP site	OP type	Cell type	Differentiation	Staging	T	N	M	Disease type	Date of last F/U	Survival State
L5MC-0101-501	C50101	34404060	1938/10/14	1	70	2009/4/15	RUL	lobectomy	Adeno.	2	IIIa	2	2	0	1	2009/9/28	S
L5FC-0102-504	C50102	882774	1966/07/27	2	43	2009/4/16	LUL/LLL	lobectomy/wedge resection	Adeno. chronic pleurisy with fibrosis	2	Ia	1	0	0	1	2009/10/21	S
L5MC-0103-501	C50103	24025560	1943/1/10	1	66	2009/4/22	RUL	lobectomy	SCC轉移性	3	Ib	2	0	2	2	2009/6/24	S
L5MC-0104-504	C50104	24444355	1927/2/4	1	82	2009/4/29	LUL	segmental resection	SCC	3	IB	2	0	0	1	2009/5/19	S
L5MC-0105-502	C50105	109423	1927/5/9	1	82	2009/4/29	RLL	segmental resection	adenosquamous	3	Ib	2	0	0	1	2009/10/27	S
L5FC-0106-501	C50106	21838451	1957/7/22	2	51	2009/4/29	RUL/RLL	lobectomy/wedge resection	Adeno.	3	Ia	1	0	0	1	2009/11/5	S
L5FC-0107-504	C50107	185324	1957/7/28	2	51	2009/4/29	RUL	lobectomy	Adeno.	3	Ia	1	0	0	1	2009/11/3	S
L5MC-0108-504	C50108	756831	1953/11/10	1	55	2009/5/6	LUL/LLL	wedge resection	cryptosporosis						5	2009/7/23	S
L5MC-0109-504	C50109	24447797	1940/12/14	1	68	2009/5/6	RUL	lobectomy	Adeno.	2	Ib	2	0	0	1	2009/10/19	S
L5FC-0110-505	C50110	24498583	1956/5/13	2	53	2009/5/6	RLL	wedge resection	Adeno.	1	Ib	2	0	0	1	2009/11/2	S
L5FC-0111-503	C50111	24422235	1967/11/3	2	41	2009/5/6	LLL	wedge resection	sclerosing hemangioma						5	2009/10/1	S
L5MC-0112-501	C50112	180393	1949/11/15	1	59	2009/5/13	LUL	lobectomy	Adeno.(BAC)	1	Ia	1	0	0	1	2009/10/1	S
L5FC-0113-510	C50113	24472045	1947/2/10	2	62	2009/5/7	RUL	lobectomy	Adeno.	2	Ib	2	0	0	1	2009/10/21	S
L5MC-0114-502	C50114	24489671	1932/5/5	1	77	2009/5/20	LLL	lobectomy	Adeno.	2	Ib	2	0	0	1	2009/9/3	S
L5FC-0115-507	C50115	18627273	1938/8/27	1	70	2009/5/20	RUL/LLL	wedge resection	AAH						1	2009/9/28	S
L5MC-0116-501	C50116	15356791	1930/2/1	1	79	2009/5/27	LLL	wedge resection	Adeno.	1	IIIa	4	0	0	1	2009/10/13	S
L5FC-0117-504	C50117	24395345	1936/11/17	2	72	2009/5/27	LUL	lobectomy	Adeno.	2	Ia	1	0	0	1	2009/9/28	S
L5MC-0118-509	C50118	24488293	1953/1/7	1	56	2009/6/3	RLL	lobectomy	Adeno	1	Ia	1	0	0	1	2009/10/1	S
L5FC-0119-501	C50119	24143673	1976/6/9	2	33	2009/6/3	LUL	segmental resection	BAC	1	Ia	1	0	0	1	2009/10/19	S
L5MC-0120-504	C50120	795315	1942/4/2	1	67	2009/6/3	RLL	segmental resection	atypical carcinoid						1	2009/10/29	S
L5FC-0121-505	C50121	19566156	1940/2/13	2	69	2009/6/3	RUL	wedge resection	Chronic granulomatous inflammation						5	2009/6/25	S
L5FC-0122-503	C50122	617395	1945/12/15	2	63	2009/6/10	RLL	lobectomy	adenocarcinoma/BAC	2	IIIa	4	0	0	1	2009/10/19	S
L5FC-0123-507	C50123	468435	1946/10/14	2	62	2009/6/10	RML/RUL	lobectomy wedge resection	granulomatous inflammation						5	2009/10/26	S
L5MC-0124-505	C50124	24626393	1941/2/20	1	68	2009/6/10	RUL	wedge resection	granulomatous inflammation c/w tuberculous						5	2009/7/6	S
L5FC-0125-507	C50125	11082814	1932/2/28	2	77	2009/6/10	LUL	lobectomy	adenocarcinoma (meta from colon)						2	2009/11/2	S
L5MC-0126-507	C50126	223216	1957/1/15	1	52	2009/6/17	LLL	Segmental resection	granulomatous inflammation						5	2009/11/5	S

個案編號	NHRI 個案編號	病歷號	Date of Death	Survival (day)	Up to therapy	History	Up OP	Meta site	Recurrence site	Recurrence date	Smoker history	Drunk history	Family history	Delayed Dx	GGO (+)	備註	multiple primary
L5MC-0101-501	C50101	24404060		166		peptic ulcer	nil					1 2	9				
L5FC-0102-504	C50102	885774		188		nil	Rt hemothorax cyst up op 3 years					2 1	3				
L5MC-0103-501	C50103	24025560		124		DM, HTN, UTI	Mouth floor SCC, post-OP, pT2N0M0, stage II					1 1	9	+			
L5MC-0104-504	C50104	24444355		20		nil	1) BPH up op in MKHS; 2) left cataract up op					3 1	9				
L5MC-0105-502	C50105	109123		181		heart disease, a additional heart vessel noted with EKG about 40+ years ago in 長庚 H. (by Dr. 張漢鈞)	1) transverse cancer up op (Rt) about 3+ years in 中山 H. 2) hysterectomy up R/T in 長庚 H.					2 2	9				
L5FC-0106-501	C50106	21838451		190		L5HVD of L5-S1 with compression of dorsal sac, left neuroforamina and left S1 nerve root	hysterectomy with post-op hypothyroidism state under levothyroxine					2 2	9				
L5FC-0107-504	C50107	185234		188		appendicitis	appendicitis up appendectomy was admitted					2 2	9				
L5MC-0108-504	C50108	756831		78		1. HBV carrier 2. IHD	nil					1 1	9		+		
L5MC-0109-504	C50109	24477797		166		1. hypertension for 1+ years 2. operation for left femoral bone fracture 10 years ago 3. asthma 4. COPD probably 5. constipation	nil					1 1	9				
L5FC-0110-505	C50110	24495583		180	GC2009/10/19B	1. hysterectomy 12 years ago 2. No known systemic disease, such as DM, HTN, Cardiovascular disease	endometrialis up					2 2	9				
L5FC-0111-503	C50111	24422235		148		1. hepatitis B 2. denied having HTN, DM 3. denied op Hx	nil					2 2	9		+		
L5MC-0112-501	C50112	180933		141		1. Small bowel angiodysplasia (jejunosum) with bleeding 2. Chronic hepatitis c	nil					1 1	9		+		
L5FC-0113-510	C50113	24473045		167		CAD	nil					2 2	9				
L5MC-0114-502	C50114	24489671		106		1. Liver abscess 11 years ago up drainage and antibiotic usage 2. TIA 3 months ago 3. HTN 4. DM	nil					2 2	9				
L5FC-0115-507	C50115	18627273		131		1. HTN 2. arrhythmia	nil					2 2	9		+	AAH 肝腫	
L5MC-0116-501	C50116	15356791		139	on D1 and D8, C	1. Suspect lung cancer over L.L.L 2. Hemoptysis 3. Bronchiectasis without acute exacerbation	nil					1 2	9	+			
L5FC-0117-504	C50117	24395345		124		nil	nil					2 2	9		+		
L5MC-0118-509	C50118	24488293		120		1. Renal stone 2. BPH without treatment	Renal stone up ESWL*2 (1st: 5 years ago, 2nd: 2009/5)					1 1	2				
L5FC-0119-501	C50119	21143673		138		nil	Bronchiectasis with carcinoma of right lung up in 2008/11					2 2	2		+	右邊BAC 左邊5個	
L5MC-0120-504	C50120	795315		148		nil	nil					2 2	9		+	右側	
L5FC-0121-505	C50121	19566156		22		nil	Cocoon adenocarcinoma up right hemicolectomy.					2 2	9				
L5FC-0122-503	C50122	617395		131	09/10/19 stage of	1. DM 2. HTN 3. Arrhythmia 4. Hyperlipidemia	Callitanea up cholecystectomy					2 2	9		+		+
L5FC-0123-507	C50123	468435		138		1. cerebral vein malformation for several years under medical control 2. bronchiectasis for months	nil					2 2	2				
L5MC-0124-505	C50124	24626393		26		TB	nil					1 2	9				
L5FC-0125-507	C50125	11082814		145		1. rectal cancer up LAR stage B2 at CGMH for 6 yrs, regular fu 4. arrhythmia without medicine	nil					2 2	9	+	+		
L5MC-0126-507	C50126	223316		141		nil	nil					3 2	1				

編號	NHRI 編號	病歷號	Date of birth	Gender	Age	OP date	OP site	OP type	Cell type	Differentiation	Staging	T	N	M	Disease Type	Date of last FU	Survival Status
L5MC-0127-501	C50127	22096132	1959/10/20	1	49	2009/6/18	LUL	wedge resection	metastatic urethelial carcinoma						2	2009/11/11	*
L5MC-0128-504	C50128	13392875	1948/5/9	1	51	2009/6/18	LUL	lobectomy	SCC	3	1	1	0	0	1	2009/10/2	*
L5FC-0119-502	C50119	22145093	1962/6/18	2	47	2009/6/22	RUL	wedge resection	adenocarcinoma	2	1b	2	0	0	2	2009/11/2	*
L5MC-0131-504	C50131	24655933	1945/6/15	1	64	2009/6/24	RUL/RLL	lobectomy/wedge resection	adenocarcinoma/AAB	2	1b	2	0	0	1	2009/7/13	*
L5FC-0132-505	C50132	24665408	1960/6/22	2	49	2009/6/24	RML RUL	wedge resection, abrasion pleurodesis	adenocarcinoma	2	IV	2	0	1	1	2009/10/29	*
L5FC-0133-506	C50133	236859	1962/7/23	2	47	2009/6/24	RLL	pleural tissue	adenocarcinoma	3	IV	3	0	1	1	2009/11/13	*
L5FC-0136-507	C50130	22739954	1951/3/1	2	58	2009/7/2	LUL	wedge resection	location organizing obstructive pneumonitis						5	2009/11/11	*
L5MC-0134-502	C50134	505536	1962/6/11	1	47	2009/7/8	RUL RML	wedge resection	AAB (atypical adenomatous hyperplasia)						5	2009/10/28	*
L5FC-0135-503	C50135	520880	1954/7/28	2	55	2009/7/8	LUL	lobectomy	adenocarcinoma		IIIa	3	2	0	1	2009/11/3	*
L5MC-0136-501	C50136	24644655	1950/7/15	1	59	2009/7/8	LUL	wedge resection	2/adenocarcinoma	1	IIIa	1	2	0	1	2009/7/30	*
L5FC-0137-503	C50137	450813	1964/9/28	2	46	2009/7/15	RML	lobectomy	(compare meeting 2x adenoma by Dr. 曾) BAC+ combined	1	Ia	1	0	0	1	2009/9/28	*
L5FC-0138-503	C50138	1830764	1942/11/23	2	63	2009/7/15	RLL	lobectomy	BAC+adenoma	2	IIIB	3	0	0	1	2009/10/22	*
L5MC-0139-502	C50139	1601376	1939/1/11	1	70	2009/7/15	LUL	Segmental resection	SCC	3	IIIB	3	0	0	1	2009/11/9	*
L5FC-0140-503	C50140	24656003	1962/8/20	2	48	2009/7/16	RUL	RUL wedge resection + lobectomy	BAC (combine meeting 2x adenoma by Dr. 曾)		IA	1	0	0	1	2009/10/19	*
L5MC-0141-503	C50141	24810185	1932/4/10	1	77	2009/7/22	RLL	lobectomy	SCC	2	IB	2	0	0	1	2009/11/9	*
L5FC-0143-506	C50143	24699650	1965/10/5	2	54	2009/7/22	RUL	wedge resection	favoring adenosing hemangioma						5	2009/11/10	*
L5FC-0142-502	C50142	302828	1951/1/22	2	47	2009/7/27	RLL	lobectomy	adenocarcinoma	2	IA	1	0	0	1	2009/11/9	*
L5FC-0144-502	C50144	312166	1931/1/23	2	78	2009/7/29	RML	lobectomy	adenocarcinoma/轉移性						2	2009/11/9	*
L5FC-0145-501	C50145	914338	1956/10/20	2	53	2009/8/6	RLL	wedge resection + complete lobectomy	BAC	1	Ia	1	0	0	1	2009/11/12	*
L5FC-0146-502	C50146	24825048	1942/2/15	2	67	2009/8/5	RUL	lobectomy	adenocarcinoma	2	Ia	1	0	0	1	2009/11/12	*
L5FC-0147-502	C50147	321595	1957/7/13	2	52	2009/8/5	RLL	wedge resection	adenocarcinoma meta from Breast 轉移性	2					2	2009/11/11	*
L5MC-0148-504	C50148	23806296	1937/4/17	1	72	2009/8/11	LUL	lobectomy	typical carcinoid tumor		Ia	1	0	0	1	2009/9/17	*
L5FC-0149-504	C50149	962618	1945/7/18	2	64	2009/8/12	LUL	lobectomy	adenocarcinoma	2	Ia	1	0	0	1	2009/11/12	*
L5MC-0150-501	C50150	17083030	1933/4/20	1	76	2009/8/12	LUL	wedge resection	SCC	3	IB	2	0	0	1	2009/11/6	*
L5MC-0151-507	C50151	13561407	1940/1/3	1	76	2009/8/12	LUL	lobectomy	adenocarcinoma	2	IB	2	0	0	1	2009/11/4	*
L5FC-0152-503	C50152	24825499	1944/10/10	2	65	2009/8/19	RUL	wedge resection	adenocarcinoma	2	Ib	2	0	0	1	2009/10/5	*

編號	NHRI 檢體編號	承慶號	Date of Death	Survival (day)	Up-OP therapy	History	Up-OP	Meta site	Recurrent site	Recurrent date	Smoke history	Drink history	Family history	Delayed Dx	GGO (+)	備註	multiple primary
L5MC-0127-501	C50127	22896132		146		1. Gastric cancer, transitional cell carcinoma 2. Metastasis L.L.L. lung tumor s/p segmental resection, bladder urethral ca s/p TURBT, and 3. Right breast cancer s/p mastectomy, lymph node Controlled well and no relapse now. 2. Allergy rhinitis, no relapse now. 3. Denied DM and HTN Tamsulosin treatment.	partial cystectomy				2	2	2				
L5MC-0128-504	C50128	13392875		106		1. Left breast cancer s/p MRM in 2006 and chemotherapy with FEC-4, Herceptin and Tamoxifen treatment.	Modified radical mastectomy, left				2	2	2				
L5FC-0129-502	C50129	22145093		133		1. Gastric ulcer 7-8 years ago 2. Had HTN	1. Surgery at 3 year-old for empyema?				2	2	2		+		
L5MC-0131-504	C50131	24658023		19							2	2	2				
L5FC-0133-505	C50132	24665408		127		HBV carrier	nil				2	2	2				
L5FC-0133-506	C50133	236859		142		nil	Ligation				2	2	2				
L5FC-0136-507	C50130	22739954		132		nil	nil				2	2	2				
L5MC-0134-502	C50134	585536		112		1. Peptic ulcer and acid reflux under PPI control 2. Right medial thigh exhibits 3 moderate fatty liver	nil				1	2	1		+	2腹AAH	
L5FC-0135-503	C50135	520880		118	6/9/2013 starts on chemotherapy	1. Lung cancer, adenocarcinoma, T3N1M0, stage IIIs s/p CCT (diaplan with subvols) s/p C3D1S2. Abdominal pain, left upper quadrant	nil				1	1	9				
L5MC-0136-501	C50136	24644655		22		nil	nil				2	2	1		+		
L5FC-0137-503	C50137	459813		75		nil	nil				2	2	9		+		
L5FC-0138-503	C50138	18302764		99		nil	nil				2	2	9				
L5MC-0139-502	C50139	16012376		117		Hypertension	nil				3	1	9				
L5FC-0140-503	C50140	24656003		95		NIL	nil				2	2	2		+		
L5MC-0141-503	C50141	24810185		110		HTN under medication	nil				3	2	9				
L5FC-0143-506	C50143	24699650		111		nil	nil				2	2	9		+		
L5FC-0142-502	C50142	302828		105		1. Cataract(OS) s/p phaco. + IOL insertion 2. Spasm of accommodation 3. CHB	nil				2	2	9				
L5FC-0144-502	C50144	312166		103		1. HTN 2. endometrial adenocarcinoma s/p op and RT 3. bronchiectasis	nil				2	2	9				
L5FC-0145-501	C50145	914338		98			nil				2	2	9		+		
L5FC-0146-502	C50146	24825048		99		1. Denied HTN, DM 2. Renal stone s/p ESWL	nil				3	3	9				
L5FC-0147-502	C50147	321595		98		1. Left breast cancer, tubular, primary LN s/p wide extramodal extension, stage IIB, s/p partial mastectomy (90-7-5) & axillary LN dissection (nil				2	2	9		+		
L5MC-0148-504	C50148	23806296		37		HTN, HIVD	HIVD s/p OP				2	2	9		+		
L5FC-0149-504	C50149	962618		92		1. Hypertension 2. CAD 3. C atract 4. Obstructive sleep apnea and obstructive sleep hypopnea 5. Insomnia	nil				2	2	9		+		
L5MC-0150-501	C50150	17803030		86		1. CVA, 3 years ago 2. Denied HTN, DM	nil				1	1	1		+		
L5MC-0151-507	C50151	13561407		84		DM under diet control without medication for 20 years	nil				2	2	1		+		
L5FC-0152-503	C50152	24825499		47		HTN for more than 10 years under medical control	nil				2	2	9				

編號	NTR(檢體編號)	病歷號	Date of birth	Gender	Age	OP date	OP site	OP type	Cell type	Differentiation	Staging	T	N	M	Disease type	Date of last FUO	Survival Status
L5FC-0151-502	C50153	24825475	1953/12/28	2	57	2009/8/19	RLL	lobectomy	adenocarcinoma	3	IIIa	2	2	0	1	2009/9/25	*
L5FC-0154-502	C50154	579785	1943/1/27	2	66	2009/8/19	RUL	wedge resection	adenocarcinoma meta from colon						2	2009/11/12	*
L5FC-0155-503	C50155	23407418	1968/3/19	2	51	2009/8/26	LLL	wedge resection	inflammatory cell infiltration						5	2009/9/30	*
L5FC-0156-503	C50156	828899	1939/9/21	2	70	2009/8/19	LUL	VATS lobectomy of LUL + R/LND	bronchioloalveolar carcinoma		Ia	1	0	0	1	2009/9/21	*
L5FC-0157-502	C50157	12196578	1952/5/11	2	57	2009/9/3	LUL	lobectomy	adenocarcinoma	2	Ia	1	0	0	1	2009/1/08	*
L5FC-0158-503	C50158	652641	1970/10/14	2	39	2009/9/2	RUL	lobectomy	adenocarcinoma	2	Ia	1	0	0	1	2009/11/10	*
L5MC-0159-502	C50159	15928018	1955/2/16	1	54	2009/9/9	RUL	lobectomy	adenocarcinoma	2 to 3	Ib	2	0	0	1	2009/11/9	*
L5MC-0160-503	C50160	24849980	1933/3/16	1	76	2009/9/14	RUL	lobectomy	adenocarcinoma	1	Ia	1	0	0	1	2009/11/4	*
L5FC-0161-502	C50161	10662317	1994/1/1	2	15	2009/9/17	LLL L/N9	wedge resection	germ cell 轉移性						2	2009/11/14	*
L5FC-0162-502	C50162	667998	1951/1/25	2	58	2009/9/17	LUL	lobectomy	adenocarcinoma		Ia	1	0	0	1	2009/10/27	*
L5FC-0163-501	C50163	24913427	1939/8/28	2	70	2009/9/30	RUL Lymph node RUL	lobectomy lymphadenectomy	adenocarcinoma/BAC		IV	2	1	1	1	2009/11/5	*
L5MC-0164-503	C50164	20024113	1964/3/26	1	45	2009/9/30	LLL/LUL	lobectomy	adenocarcinoma	2	Ia	1	0	0	1	2009/10/21	*
L5FC-0165-505	C50165	23426596	1964/10/4	2	45	2009/9/30	LLL	lobectomy	BAC		Ia	1	0	0	1	2009/11/13	*
L5MC-0166-501	C50166	24656433	1938/2/19	1	71	2009/9/30		video-assisted thoracoscopic surgery (VATS) excision	thyroid	3	IV	4	0	X	4	2009/11/9	*
L5MC-0167-503	C50167	287332	1955/1/2	1	54	2009/10/7	LUL	wedge resection	inflammation and anthracosis						5	2009/10/19	*
L5MC-0168-501	C50168	11174568	1937/3/29	1	72	2009/10/7	LUL	lobectomy	adenocarcinoma	3	Ib	2	0	0	1	2009/11/12	*
L5FC-0169-502	C50169	20488817	1968/12/30	2	41	2009/10/7	RML	lobectomy	metastatic cervical carcinoma/轉移性						2	2009/10/22	*
L5FM-0170-503	C50170	24451925	1978/1/26	1	31	2009/10/7	LUL	lobectomy	granulomatous inflammation						5	2009/10/22	*
L5FC-0171-503	C50171	24912841	1967/3/14	2	42	2009/10/8	LUL	lobectomy	adenocarcinoma	3	IIIa	3	2	0	1	2009/11/12	*
L5FC-0172-505	C50172	18861617	1943/9/25	2	66	2009/10/8	LLL	SCC	SCC	2	Ib	2	0	0	1	2009/10/21	*
L5FC-0173-502	C50173	24913401	1966/9/29	2	43	2009/10/12	RLL+RML	lobectomy + Wedge resection	adenocarcinoma (meeting 後改爲腺癌)		IIIa	4	0	0	1	2009/11/12	*
L5FC-0174-503	C50174	24913750	1963/2/26	2	46	2009/10/13	RML	lobectomy	Adeno	3	IIIa	1	2	0	1	2009/11/12	*
L5MC-0175-504	C50175	10807902	1971/2/1	1	37	2009/10/14	LLL	wedge resection	bronchioloalveolar carcinoma/meeting 改爲Adeno		Ia	1	0	0	1	2009/11/12	*
L5MC-0176-501	C50176	24968502	1957/3/16	1	52	2009/10/21	RLL	wedge resection	TB						5	2009/11/9	*
L5FC-0177-501	C50177	19659980	1933/8/14	2	76	2009/10/21	RUL	wedge resection	Adeno		Ia	1	0	0	1	2009/11/5	*
L5MC-0178-510	C50178	24998583	1954/11/25	1	55	2009/11/5	RUL	lobectomy	Adeno	2	Ia	2	0	0	1	2009/11/15	*

編號	NERI編號	病歷號	Date of Death	Survival (day)	up of therapy	History	up OP	Meta site	Meta date	Recurrence site	Recurrence date	Smoke history	Drink history	Family history	Delayed Dx	GGO (+)	備註	multiple primary
L5FC-0153-502	C50153	24825475		37		NIL						2	2	1				
L5FC-0154-502	C50154	579785		85		Malignant neoplasm of rectum	Malignant neoplasm of rectum s/p OP one and a half year ago					2	2	9	+			
L5FC-0155-503	C50155	23407418		35		NIL	NIL					2	2	2		+		
L5FC-0156-503	C50156	828999		33		NIL	NIL					2	2	9				
L5FC-0157-502	C50157	12196578		35		bil. ovarian resection 28 years ago	NIL					2	2	1		+		
L5FC-0158-503	C50158	652641		69		Allergic rhinitis	NIL					2	2	2		+		
L5MC-0159-502	C50159	15928018		61			1. Analysing pseudotubercle s/p op 2. gastric ulcer s/p half gastrectomy					2	2	9				
L5MC-0160-503	C50160	24849900		51			NIL					1	2	9				
L5FC-0161-502	C50161	18662317		58		Left vulvar mixed germ cell tumor stage III	0961220. Simple vulvectomy and BILND					1	1	1				
L5FC-0162-502	C50162	667998		40			1. Right cancer s/p laparoscopic AR 2. acute appendicitis s/p					2	2	2				
L5FC-0163-501	C50163	24913427		36			1. left forearm fracture s/p op for 5 years					2	2	9				
L5MC-0164-503	C50164	28024213		21			1. appendicitis s/p appendectomy 2. right neck benign mass s/p op					1	1	9				
L5FC-0165-505	C50165	23420596		44								2	2	9	+			
L5MC-0166-501	C50166	24696423		40		CAD documented by MDCT during health exam						2	2	9				
L5FC-0167-503	C50167	287332		12		1. Rheumatoid arthritis (with medication of 2 years) 6 years ago. 2. Lipoma underwent surgery.						2	2	9				
L5MC-0168-501	C50168	11174568		36		1. Left lung cancer, CT IN080 2. Simple chronic bronchitis 3. Allergic rhinitis 4. Abdominal ulcer	1. Lung cancer s/p CT with RAH+RSO+LS+BPLND+suspension of L4+5, with lung metastasis s/p 2 cycle salvage CT with FU(1000mg/m2) D1+D3 ...					1	2	9				
L5FC-0169-502	C50169	20488817		15								2	2	9				
L5FM-0170-503	C50170	24451925		15		NIL	NIL					2	3	9		+		
L5FC-0171-503	C50171	24912841		35		1. Dysmenorrhea and irregular menstrual cycle for many years 2. HBV carrier						2	2	9				
L5FC-0172-505	C50172	18061617		13		1. Hepatitis c without mention of hepatic carcinoma or unspecified 2. Hypertension 3. CVA accident 4. Cervical cancer CIN III						1	1	9				
L5FC-0173-502	C50173	24913601		31		Cesarean section in MK 88 8814 VATS						2	2	9				
L5FC-0174-503	C50174	24913750		30		1. Past Medical History						2	2	9				
L5MC-0175-504	C50175	18887902		29		NIL						3	2	9		+		+
L5MC-0176-501	C50176	24968502		19		Comminuted fracture on both legs cause by an accident(1997), being treat with surgery(orthopedic surgery)						1	1	9				
L5FC-0177-501	C50177	19659880		15		1. Transient ischaemic attack 2. Hypertension 3. CVA in September 2003 4. Urinary prolapse s/p ...						2	2	9		+		
L5MC-0178-510	C50178	24998583		10		otherwise denied DM, CAD, CVA or other systemic disease.						2	2	9		+		